Intelligent Ultrasound Group PLC CE approval of ScanNav Anatomy: PNB (1969V)
2021年4月13日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMIUG
RNS Number : 1969V
Intelligent Ultrasound Group PLC
13 April 2021
13 April 2021
Intelligent Ultrasound Group plc
("IUG" or the "Company")
CE approval of ScanNav Anatomy: Peripheral Nerve Block
UK launch expected in Q2
Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound
artificial intelligence (AI) software and simulation company,
announces CE approval of ScanNav Anatomy: Peripheral Nerve Block
("ScanNav PNB").
ScanNav Anatomy uses the latest AI technology to automatically
highlight the live ultrasound image to enhance the accuracy and
standardisation of ultrasound image interpretation, by making it
easier to identify key anatomical structures. This supports the
performance of healthcare professionals who are suitably qualified
but who perform ultrasound-guided procedures on a less frequent
basis.
ScanNav PNB supports nine common peripheral nerve blocks (a form
of local anaethesia) and will be sold as a stand-alone device, with
in-built AI software, that can be plugged into existing
anaesthesiology ultrasound machines. The device will provide
clinicians with continuous feedback from real-time highlighting of
their live ultrasound. Users can also re-familiarise themselves
with blocks that are carried out less frequently using the system's
integrated 3D animations.
ScanNav PNB is also available as a training simulator for
medical learning on volunteers, prior to patient contact.
Increasingly, ultrasound-guided peripheral nerve blocks are
being used as a prudent alternative to general anaesthesia, but not
all anaesthetists have the specialist knowledge of ultrasound
anatomy to perform them. Through the adoption of ScanNav PNB, it is
hoped that hospitals will be able to increase the number of
ultrasound-guided nerve blocks that they can perform.
The Company intends to sell the stand-alone system to the UK
market using its existing in-house sales resources, with an
expected launch in Q2 2021. In addition, the Company continues to
progress the product's FDA regulatory filing to enable a version of
the product to be sold in the US, as well as seeking to licence an
integrated version of the product to the major ultrasound
manufacturers.
Lead clinician and consultant anaesthetist, Dr David
Burckett-St.Laurent, said: "ScanNav PNB will help tip the balance
of safety and confidence in favour of performing regional
anaesthesia. I feel privileged to have been working with a company
that is leading the world in developing AI-based ultrasound
software. Our aim has been to make a real clinical difference to
patients by increasing the availability of regional anaesthesia
through cutting edge technology. It is very exciting that the
product has now moved out of the lab and into clinical
practice."
Stuart Gall, CEO of Intelligent Ultrasound Group plc, commented:
"We're delighted to have received CE mark approval for our second
AI product. Building on the success of ScanNav Assist, our first
obstetric AI software that is integrated into GE Healthcare's
recently launched SWIFT ultrasound machine, ScanNav Anatomy PNB
will launch into the anaesthesiology ultrasound market and
continues the Group's expansion into AI-based real-time clinical
ultrasound image analysis. We are particularly pleased that many of
the independent clinicians who used ScanNav PNB during product
testing think that it would benefit them in their everyday clinical
practice."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information, please contact:
Intelligent Ultrasound Group www. intelligentultrasound.com
plc
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor Tel: +44 (0)20 7397 8900
and Broker
Giles Balleny / Max Gould (Corporate
Finance)
Dale Bellis / Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44
(0)7980 541 893
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) develops artificial
intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market and hi-fidelity virtual
reality simulators for the ultrasound training market. Based in
Cardiff in the UK and Atlanta in the US, the Group operates two
divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make
ultrasound machines smarter and more accessible. Products in the
market include:
ScanNav Assist
ScanNav Assist uses machine-learning based algorithms to
automatically identify and grade ultrasound images. GE Healthcare's
SonoLyst software on their Voluson SWIFT ultrasound machine
incorporates the ScanNav Assist AI technology and has received
510(k) clearance from the FDA for sale in the USA. SonoLyst is the
world's first fully integrated AI tool that recognises the 20 views
recommended by the International Society of Ultrasound in
Obstetrics and Gynaecology mid-trimester practice guidelines for
fetal imaging.
ScanNav Anatomy
ScanNav Anatomy PNB uses machine-learning based algorithms to
simplify ultrasound-guided needling by providing the user with
real-time AI-based anatomy highlighting software for a range of
medical procedures. ScanNav Anatomy has received CE approval and
has also been submitted for FDA regulatory approval. ScanNav
Anatomy PNB is therefore not available for sale in the US or any
other territory requiring government approval for this type of
product.
Simulation Division
Focusses on hi-fidelity ultrasound education and training
through simulation. Its main products are the ScanTrainer OBGYN
training simulator, the HeartWorks echocardiography training
simulator, the BodyWorks Eve Point of Care and Emergency Medicine
training simulator with Covid module and the new AI-based Anatomy
PNB training simulator. To date over 1,000 simulators have been
sold to over 600 medical institutions around the world.
www.intelligentultrasound.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCELLFFFZLLBBB
(END) Dow Jones Newswires
April 13, 2021 02:00 ET (06:00 GMT)
Intelligent Ultrasound (LSE:MED)
過去 株価チャート
から 1 2025 まで 2 2025
Intelligent Ultrasound (LSE:MED)
過去 株価チャート
から 2 2024 まで 2 2025